These stocks are flying under the radar as U.S.-Iran war continues and could see big gains, says Citi

S&P 500 has dropped nearly 8% in March amid the U.S.-Iran war and rising oil prices; Citi screened for stocks that can sidestep volatility and have uncrowded upside catalysts. Delta Air Lines is down 3.8% this month and nearly 9% YTD in 2026, but consensus LSEG analyst ratings are a buy with price targets implying roughly 25% upside. Summit Therapeutics is up 2.4% since the conflict began, has a long crowding composite of 18.1%, and 13 of 18 analysts rate it buy/strong buy.

Analysis

Geopolitical-driven oil and volatility repricing is creating an environment where idiosyncratic, low-positioning stories can outperform macro-correlated names. When a stock has limited long crowding, positive fundamental news (earnings beats, regulatory wins, partnership announcements) tends to transmit more directly into price because there are fewer forced liquidations and fewer competing mandate-driven sellers; the reaction window is typically days-to-weeks but can gap into months if the catalyst sequence stacks.

Airlines face an asymmetric shock: energy-driven cost pressure now, but revenue elasticity and route/mix optionality can restore margins faster than headline risk implies. Carriers with stronger premium yield engines, diversified international networks and loyalty economics can monetize corporate demand recovery within 2–6 quarters and re-rate faster than peers. However, higher jet fuel for 1–3 quarters materially raises break-even RASM for marginal seats and will force capacity discipline (or fare resets) that can compress volume growth in leisure segments.

Small-cap biotech with low crowding is the classic “thin market, fat move” setup: a single positive clinical or partner data release can produce outsized returns, but dilution and binary trial risk mean expected value is dominated by event timing and financing risk. For financials and large-cap banks, geopolitical volatility lifts trading revenues but increases tail-credit provisioning uncertainty; this creates mixed short-term earnings signals and keeps multiples volatile for the next 1–4 quarters.

Practical implication: prioritize catalyst-tied, low-crowding long exposure sized to event risk and protected against macro drawdowns, and pair these with short or hedged positions in more crowded, macro-sensitive peers to isolate idiosyncratic upside. Time horizons: days–weeks for event trades, 3–12 months for structural re-rating, multi-year only if franchise-level fundamentals change.

Key Decisions for Investors

• Long DAL (1–2% NAV, 6–12 month horizon): Buy shares and hedge downside with a 3–6 month 10% OTM put. Rationale: capture idiosyncratic revenue recovery while limiting black‑swan downside from an oil spike; target asymmetric payoff of ~2:1 upside/downside if travel mix normalizes within 6–12 months.
• Pair trade — Long DAL / Short UAL (equal notional, 3–6 month horizon): Size 0.5–1% NAV net exposure. Rationale: isolate premium-international mix vs cyclical domestic exposure; stop-loss if pair diverges >15% against position. Expected payoff: 1.5–3x if DAL recovers on premium demand while UAL lags.
• Event-driven SMMT (0.25–0.5% NAV, event-tied 1–3 month options): Buy a call spread (near-term ATM to ~40% OTM) sized to max known capital at risk and hedge by shorting 0.25% NAV of IBB to neutralize sector move. Rationale: low crowding amplifies positive news; cap downside to option premium and limit dilution exposure. Target: 3x+ on successful catalyst, limit loss to premium paid.
• Macro hedge (0.5% NAV, 1–3 month): Buy VIX calls or a short-dated equity hedge (SPX put spread) to protect event-driven longs during elevated geopolitical risk. Rationale: prevents forced liquidations of idiosyncratic positions if broad risk-off accelerates; expect hedge to pay if S&P drops >5% in short window.